XNAS
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2024-11-15 | FY 2024 | — | -0.07 | — | $15.6M | — | +11.16% | +26.04% | -27.13% |
| 2024-03-27 | H1 2024 | — | -0.02 | — | $4,205 | — | — | — | — |
| 2023-09-05 | FY 2023 |
| — |
| -0.08 |
| — |
| $15,562 |
| — |
| +10.89% |
| +0.01% |
| -5.94% |
| 2023-03-07 | H1 2023 | — | -0.06 | — | $93,188 | — | +0.13% | -1.82% | +9.85% |
Showing last 4 quarters.